Founded in Cambridge, United States, Ribon Therapeutics is a clinical-stage biotechnology company focused on pioneering the development of first-in-class small molecule inhibitors. Their core mission is to discover and develop novel therapeutics that target cellular stress pathways, specifically aimed at blocking the survival mechanisms of cancer cells. Ribon's product pipeline includes inhibitors like RBN-2397, a PARP7 inhibitor, and RBN-3143, a PARP14 inhibitor, which are designed to disrupt NAD+-utilizing enzymes critical for cancer cell survival.

Ribon Therapeutics is backed by a distinguished team of scientific advisors and a robust board of directors, with significant investments from leading venture capital firms. The company has achieved key milestones, including advancing its lead compounds into clinical trials and publishing influential scientific research. Ribon's innovative approach has the potential to significantly impact cancer treatment by targeting the fundamental stress support pathways that cancer cells rely on, offering new hope for patients with hard-to-treat cancers.